Table 2.
Effect of Aripiprazole on Electrocardiographic Measurements for Subjects Completing the Study (n=24)
| |
Change |
% Change |
||
|---|---|---|---|---|
| Interval | Mean (SD) | Range | Mean (SD) | Range |
| PR | 3 (11) | −22–22 | 2.8 (8.3) | −15.3–18 |
| QRS | 0 (9) | −19–16 | 1.0 (10.4) | −21.3–21.6 |
| RR | 0.02 (0.12) | −0.28–0.17 | 4.3 (15.7) | −35.3–22.8 |
| QT | 2 (24) | −72–32 | 0.8 (6.6) | −18.8–9.4 |
| QTcB | −4 (16) | −54–23 | −0.9 (3.8) | −11.5–6.1 |
| QTcN | −2 (13) | −41–19 | −0.5 (3.2) | −9.3–4.8 |
| QTcF | −2 (13) | −38–19 | −0.4 (3.2) | −8.7–4.9 |
QTcB=Bazett's correction (
); QTcN=FDA Neuropharmacology Division's correction (QT/RR0.37); QTcF=Fridericia's correction (
).
Aripiprazole had a very minor effect on the electrocardiographic parameters measured. The absolute change is expressed in ms. The % change is reported in percentages.